























Intracerebroventricular streptozotocin induces 
behavioral impairments and increases short‑term C3 
gene expression in the hippocampus of Wistar rats
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A non‑transgenic rat model based on intracerebroventricular injection of streptozotocin (STZ) has been used as an animal model 
to investigate mechanisms associated to the late onset of sporadic Alzheimer’s disease, such as anatomical and behavioral 
impairments. However, molecular aspects related to gene expression, mainly in the hippocampus, require more investigation. Thus, 
this study evaluated the early and late cognitive functions and hippocampal gene expression after STZ administration. Male Wistar 
rats were divided into 4 groups: STZ (injected bilaterally), control group for the early memory function evaluation (1 month after 
surgery = phase  1, same volume of vehicle), and the same treatment for the late memory function evaluation (4  months after 
surgery = phase 2). The animals were observed in the elevated plus maze to assess behaviors related to anxiety, risk‑assessment 
and fear‑related memories. The behavioral tests were followed by brain removal and hippocampal dissection for RNA extraction and 
qRT‑PCR to assess the expression levels of 4 Alzheimer’s disease related genes: Mapt, Apoe, C3 and Ps‑1. Animals from both phases 
showed increased time percentage and number of entries into the open arms, indicating risk behavior associated with anxiety, and 
an increased time percentage in the center square for both exposures (re‑test) when compared to the control group, suggesting 
working memory impairment related to an aversive event. Statistical analyses indicated that the STZ group presented alterations 
in anxiety, memory and risk assessment responses. Additionally, one month after STZ administration, C3 gene assays revealed an 
increased expression. Therefore, current data indicate that neuroinflammatory events linked to the expression of pro inflammatory 
cytokines such as C3 are related to memory, anxiety and decision‑making alterations.
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INTRODUCTION 
Alzheimer’s disease (AD) is a progressive neurode‑
generative disease which is clinically characterized by 
dementia and neurobehavioral impairments mainly on 
memory functions (Kar et al., 2004). Additionally, sig‑
nificant behavioral changes such as progressive memo‑
ry loss, anxiety, agitation and irritability are observed. 
AD is categorized into two types: late‑onset spo‑
radic AD and early‑onset familial AD (Dorszewska et 
al., 2016). The first one represents 95% of all the cases 
(Bartolotti and Lazarov, 2016). Sporadic AD is a mul‑
tifactorial disease caused by genetic, epigenetic, en‑
vironmental and metabolic aspects (Iqbal and Grund‑
ke‑Iqbal, 2005) such as decreased glucose metabolism 
and energy consumption (Heiss et al., 1991; Gong at 
al. 2006).
The primary pathological characteristics of AD are 
neurofibrillary tangles, intraneuronal lesions com‑
posed of an aggregation of hyper phosphorylated TAU 
protein and amyloid deposits, constituted of accumu‑
lated Aβ peptide (Goedert et al., 1991).
Studies have shown that ε4 allele of apolipoprotein 
E (APOE) gene is a key component related to genet‑
ic risk factor for AD (Pericak‑Vance et al., 1991; Liu 
et al., 2013). The complete absence of fibrillar Aβ in 
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Apoe‑null AD transgenic mice (Holtzman et al., 2000) 
suggested that this gene may be a key participant in 
Aβ fibrillization. 
Moreover, mutations in presenilin‑1 (PS‑1) gene 
also lead to amyloid deposits in the mouse brain (Duff 
et al., 1996). Another typical pathological character‑
istic of AD is the presence of neurofibrillary tangles 
(Nelson et al., 2009). They are aggregates of MAPT‑en‑
coded microtubule‑associated protein TAU that is di‑
rectly involved in the organization, stabilization, and 
dynamics of microtubules (Weingarten et al., 1975; 
Cuchillo‑Ibanez et al., 2008; Dubey et al., 2008). 
Activation of microglia, which leads to higher lev‑
els of inflammatory proteins expression in the brain 
(Xiang et al., 2006), have been identified as biomark‑
ers of AD genesis. Complement factor C3 is a central 
component of the complement system and a key in‑
flammatory protein activated in Alzheimer’s disease 
(Maier et al., 2008). 
Transgenic mouse is frequently used as a model to 
mimic familial AD symptoms and molecular aspects 
(Elder et al., 2010). Aiming to study the mechanisms 
associated with sporadic AD, an intracerebroventric‑
ular injection of streptozocin (icv‑STZ) in rats has 
been consolidated as an animal model (Grünblatt et 
al., 2007; Grieb, 2016; Lester‑Coll et al., 2006). STZ, 
a glucosamine‑nitrosourea compound, is a DNA al‑
kylating agent, which enters the cells exclusively via 
GLUT2 glucose transport protein, leading to death of 
insulin‑producing cells (Kamat, 2015). Thereby there 
is a chronically decrease of cerebral glucose uptake 
which produces multiple effects similar to molecular, 
pathological, and behavioral features of Alzheimer’s 
disease (Grieb, 2016). 
Studies have already described cognitive alter‑
ations, such as deficits in spatial memory 40 days after 
icv‑STZ (Shoham et al., 2003). Additionally, 3 h after 
STZ injections, disruption of working memory has 
been observed followed by degenerative processes in 
the hippocampus at 1 and 15 days after STZ injections. 
Furthermore, memory disruptions increase over time 
(Santos et al., 2012) as demonstrated by mice that re‑
ceived icv‑STZ and showed impairment in learning 
and spatial memory 21 days after STZ administra‑
tion (Chen et al., 2012). Bao and coworkers (2017) also 
found that icv‑STZ remarkably induced impairment 
on learning and memory functions, besides loss of 
dendritic and synaptic plasticity in rats, 37 days after 
icv‑STZ. Gene expression analysis in this animal mod‑
el has been performed as an attempt to elucidate mo‑
lecular aspects of the disease (Grünblatt et al., 2004; 
Hosseinzadeh et al., 2015; Gupta et al., 2018). 
In spite of those behavioral experiments per‑
formed in icv‑STZ model, more studies related to be‑
havior and gene expression in AD genesis in a broader 
period are essential for the comprehension of the dis‑
ease progression. Differences in gene expression as‑
sociated with behavioral aspects in icv‑STZ rat model 
can lead to new perspectives regarding prevention 
and treatment of sporadic AD, the most prevalent type 
observed in the population. Therefore, the aim of this 
study was to investigate a possible relationship be‑
tween neurobehavioral impairments and gene expres‑
sion of Mapt, Apoe, C3 and Ps‑1 in the hippocampus of 
icv‑STZ rat model in two phases; early (1 month after 
icv‑STZ) and late (4 months after icv‑STZ) expression. 
METHODS
Thirty‑two male Wistar rats at the age of 90 days, 
weighing in average 350 g, were used in this study. The 
animals were obtained from the animal facility at the 
Universidade Positivo and remained under controlled 
conditions including light/dark cycle of 12 h (07:00 am 
to 07:00 pm) and temperature of 21°C with water and 
food ad libitum. 
The animals were divided into four groups of eight 
rats each (n=8 per group) and housed into subgroups 
of four animals in opaque standard laboratory cages. 
Two groups were used as a control, in which icv in‑
jections of citrate buffer were administered (control 
group) and the other two groups received strepto‑
zotocin via icv (STZ group). One control and one STZ 
group were submitted to the elevated plus maze (EPM) 
and had their brains removed one month after the in‑
jections (phase 1). Four months later, the other two 
groups were submitted to the same procedure to eval‑
uate short and long‑term effects of STZ, respectively 
(phase 2, Fig. 1).
The experiments were carried out in accordance 
with the guidelines of the Brazilian College for Ani‑
mal Experimentation and in accordance with the Na‑
tional Institutes of Health Guide for the Care and Use 
of Laboratory Animals. All the procedures involving 
animal experimentation were approved by the Ethics 
Committee on Animal Use in Research of Universidade 
Positivo under protocol number 322.
Rats were anesthetized with a combination of ket‑
amine (90 mg/kg) and xylazine (12 mg/kg) followed 
by their positioning in a stereotaxic frame.
A sagittal incision in the midline was performed 
until bregma became clearly visible. Based on Paxinos 
and Watson (2013), the stereotaxic coordinates used 
for the application of STZ (Sigma Aldrich) or 0,05 M 
Citrate Buffer pH 4,5 (solution of citric acid, Merck 
and sodium phosphate, Merck) bilaterally into the 
lateral ventricles from bregma were: ‑0.96 mm in the 
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anteroposterior axis, 1.8 mm in the medial‑lateral axis 
and 3.6 mm in the dorsal‑ventral axis.
Sixteen rats were submitted to bilateral injections 
of STZ (3 mg/kg) freshly dissolved in citrate buffer to 
assess the effects of icv‑STZ injection (Salkovic‑Petris‑
ic et al., 2011; Santos et al., 2012). The alterations ob‑
served after this dose administration induce damage 
in essential structures for learning and spatial mem‑
ory (Shoham et al., 2003), but do not cause undesired 
systemic effects. The same vehicle at the same stereo‑
taxic coordinates was injected for the control group. 
A volume of 5 μL was injected in each hemisphere. 
Bilateral injections ensure homogeneous drug disper‑
sion in both hemispheres, generating no laterality‑de‑
pendent effects. 
Elevated plus maze
Anxiety, risk assessment and aversive episodic 
memory were evaluated through EPM tasks. Episod‑
ic memory was evaluated by the test‑retest paradigm, 
which consists of repeated exposures to the EPM in 
a pre‑established inter‑trial‑interval (Sharma and 
Kulkarni, 1992; Tanyeri, 2014; Mutlu et al., 2015). 
Anxiety was assessed using the time percentage and 
absolute number of entries in the open arms of the 
apparatus (Lamprea et al., 2000; Carobrez et al., 2001; 
Rasmussen et al., 2001) and risk assessment related 
behaviors was evaluated using time percentage spent 
in the center square (Rodgers et al., 1997).
The EPM presented two opposite facing open arms 
(50 × 10 × 0.5 cm), two closed arms (50 × 10 × 10 cm) 
and a center square (4 cm long × 4 cm wide) forming 
a plus shape. Each rat was placed in the center square 
facing a closed arm, under constant and indirect light 
for 5 min. After this procedure, the maze was cleaned 
with alcohol 70% and a retest was conducted with in‑
ter‑trial‑interval (ITI) of 5 min. A retest 5 min after 
the first exposure has shown that rats are able to use 
working memory, a well‑known hippocampal depen‑
dent cognitive function, to acquire and remember 
about the aversive memory represented by the expo‑
sure to an open and elevated environment such as the 
EPM in the first exposure (Da Silva et al., 2019).
Behavioral patterns were measured from the time 
each animal performed the movements, using Pluz‑
MZ v1.1 Software. During all the evaluation period, 
groups were randomly tested and the investigator was 
unaware to the experimental group’s composition. 
Fig. 1. Representative flowchart of experimental groups and main methodologies used in this study, including behavioral tasks and real‑time quantitative 
reverse transcription PCR (qRT‑PCR). Animals that received the drug are represented by STZ group and those whose did not, by control group. Besides 
that, phase 1 and phase 2 represents short (one month after surgery) and long (four months after surgery) term exposures.
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RNA extraction 
Five animals from each group were submitted to 
RNA extraction and gene expression analyses. Animals 
were euthanized through deep isoflurane inhalation. 
After brain removal, hippocampus bilateral dissec‑
tion was performed using a stereomicroscope. Then, 
the tissue was placed into a microtubule containing 
RNAlater™ Stabilization Solution (Thermo Fisher Sci‑
entific) for the RNA stabilization and protection. Hip‑
pocampal samples were stored at ‑20°C. After this pro‑
cedure, a complete disruption of tissue structure and 
cell membranes was performed to release all the RNA 
contained in the sample using Trizol™ Reagent (Ther‑
mo Fisher Scientific). 
PureLink™ RNA Mini Kit (Thermo Fisher Scientif‑
ic) was used for total RNA extraction. Furthermore, 
TURBO™ DNase (Thermo Fisher Scientific) was added 
to eradicate DNA contamination from the total RNA 
preparations. The RNA purity, integrity and quanti‑
fication were determined by NanoDrop® 200UV‑Vis 
Spectrophotometer (NanoDrop Technologies), 1.5% 
agarose gel electrophoresis (supplementary Fig. 1A) 
and Quantus™ Fluorometer (Promega), respectively. 
Reverse transcriptase reaction 
One µg of total RNA was reverse‑transcribed by 
High‑Capacity cDNA Reverse Transcription Kit (Ther‑
mo Fisher Scientific) to generate cDNA. Reactions 
were performed under RNase‑free conditions. These 
procedures consisted in adding 2 µL 10x RT Buffer, 
0.8 µL 25x dNTP Mix, 2 µL 10x RT Random Primers, 
1 µL MultiScribe Reverse Trancriptase 50U/µL, 4.2 µL 
nuclease free water, and 10 µL RNA (100 ng/µL) total‑
ing 20 µL of reaction volume. Samples were incubat‑
ed at 25°C for 10 min, 37°C for 2 h and 85°C for 5 min 
to inactivate reverse transcriptase in a Mastercycler 
personal (Eppendorf). Reverse transcription without 
enzyme was also performed as a negative control to 
assess possible gDNA contamination.
Primer design 
Primer pairs for Apoe, Mapt and C3 were designed 
using Primer Express Software v.3.0.1 (Thermo Fish‑
er Scientific). Gene sequences were obtained from 
Ensembl database (http://useast.ensembl.org/) which 
was also used to examine the genomic structure of 
genes and their transcripts. Primer sequence for Ps‑1 
was obtained following previous studies (Ricceri et 
al., 2004) and β‑actin was selected as reference gene 
for gene expression analysis (Yamada et al., 2005; So‑
ria‑Fregoso et al., 2008; Hatami et al., 2010; Blanco et 
al., 2012). Primers covered at least two exons or were 
designed to amplify exons separated by large introns 
to avoid false‑positive amplification of contaminating 
genomic DNA in the experimental samples. 
All primer sequences were analyzed using BLAST 
tool to confirm the specificity to the target gene. The 
results showed absence of multi‑locus matching indi‑
vidual primer sites. Polymerase chain reaction (PCR) 
and electrophoresis were performed to confirm the 
fragment size (supplementary Fig. 1B). Melting curve 
analysis was also performed to evaluate primer speci‑
ficity (supplementary Fig. 2). Table I presents data and 
characteristics of each primer pair.
qRT‑PCR analyses
The first‑strand cDNA was used for qRT‑PCR us‑
ing RT2 SYBR® Green qPCR Mastermix (Qiagen). Re‑
actions were performed in StepOnePlus Real‑Time 
Table I. Primer details for target genes (Apoe, Mapt, C3 and Ps‑1) and for reference gene (β‑actin). 
Abbreviation Gene Name Primer Forward (F)  and Reverse (R) Exon
Amplicon size 
(bp)*
Apoe Apolipoprotein E F: AGCTGCAGAGCTCCCAAGTCR: CCGCCTGCACCTCTTTAGC
3
4 150
Mapt Microtubule Associated protein TAU F: CCAGTAAGAGCCGCCTACAGAR: GGACGTTGCTAAGATCCAGCTT
9
10 150
C3 C3 F: GACCTGCGACTGCCCTACTCTR: CCGTCTTCAACCACTTCATCAG
20
21 272
Ps‑1 Presenelin‑1 F: CATTCACAGAAGACACCGAGAR: TCCAGATCAGGAGTGCAACC
5
7 261
Β‑actin Beta actin F: TGTCACCAACTGGGACGATAR: GGGGTGTTGAAGGTCTCAAA
3
4 165
*Amplicon size is represented by the number of base pairs (bp).
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PCR System (Thermo Fisher Scientific). For each reac‑
tion, 50 ng cDNA was used (2 µL), adding 1x RT2 SYBR 
Green Mastermix (10 µL), 0.2 mM of the forward and 
reverse primers (except for C3 and Ps‑1 reactions, in 
which 0.1 mM was used) and 7.2 µL nuclease‑free wa‑
ter (Thermo Fisher Scientific), totaling 20 μL reaction 
volume. Amplification was performed by 40 cycles at 
94°C for 15 sec and 60°C for 1 min. 
Data analysis 
The dependent measures analyzed in the EPM in‑
cluded: time spent and absolute number of entries 
both in the open arms (provided indexes risk behavior 
and anxiety) and closed arms (locomotor activity), as 
well as in the center square (indexes of risk assess‑
ment and decision making). 
All data were analyzed by repeated measures anal‑
ysis of variance (ANOVA), with groups as the between 
and sessions and trials as the within‑subject’s factors. 
Separate ANOVA’s were performed for each measure. 
Gene expression analyses were performed using 
the data generated by StepOne Software v.2.3 (Ther‑
mo Fisher Scientific). For the statistical analyses, 
fold change (2(‑ΔΔCt)) of each sample was used as the 
relevant dependent variable with the administration 
of STZ (present or not) and time of testing (short or 
long‑term effect) representing the treatment, or “cat‑
egorical factors”, using ANOVA analysis. When neces‑
sary, Tukey’s post hoc test was used to verify specific 
differences among experimental groups. All the anal‑
yses were performed using Statistica 8.0 software 
(StatSoft, Inc., 2011). P values ≤ 0.05 were considered 
significant. 
RESULTS
Intracerebroventricular STZ increases risk 
behavior and memory impairments
Animals from both phases were exposed to the 
EPM, where behavioral parameters such as time per‑
centage and absolute number of entries in the open 
and closed arms (anxiety, episodic memory), as well 
as number of crosses in the center square (risk assess‑
ment, decision‑making) were measured and recorded.
STZ group presented increased time percentage 
(Fig. 2A) and absolute number of entries (Fig. 2B) into 
the open arms when compared with the control group 
(group effect: F(1,27)=11,71; p<0.01), suggesting a risk be‑
havior associated with anxiety. Additionally, the STZ 
group presented an increased time percentage in the 
center square (Fig. 2C) in comparison to the control 
group (group × trial effect: F(1,27)=21,23; p<0.01), indi‑
cating a risk assessment‑related behavior and episodic 
memory impairment. Additionally, STZ exposure re‑
sulted in an increased number of crosses in the center 
square in both trials (Fig. 2D) when compared with the 
control group (group × trial effect: F(1,27)=10,08, p<0.01), 
emphasizing an increased risk behavior and memory 
impairment associated with icv STZ administration. 
The proportion of entries into the closed arms 
was significantly higher in STZ group (group effect: 
F(1,27)=4,29, p=0.04) than the control (Fig. 2E), indicat‑
ing high locomotor activity. 
Although no significant differences were found be‑
tween phase 1 and phase 2, both STZ groups showed 
alterations in anxiety, memory and risk assessment 
related behaviors.
Ps‑1, Apoe and Mapt gene expression  
were not affected by STZ administration
Considered as part of important processing path‑
ways of β amyloid peptide, Ps‑1 (p=0.40) (Fig. 3A) and 
Apoe (p=0.24) (Fig. 3B), genes which are strictly related 
to the formation of Aβ plaques were not significantly 
affected by the STZ treatment during the evaluation 
period.
Besides Aβ plaques, neurofibrillary tangles are also 
an important pathological characteristic for AD. Mapt 
encodes TAU protein and its upregulation has been ob‑
served in both AD human brains and animal models. 
Although this study has not found a significant differ‑
ence between the treatment groups, there was a trend 
in which the STZ group showed a marginally increased 
expression of Mapt (group × phase effect; F(1,14)=3,33, 
p=0.08) in phase 1 (Fig. 3D).
Intracerebroventricular administration  
of STZ increases C3 expression 
Neuroinflammation is one of the most remarkable 
events that accompanies neurodegeneration process‑
es. C3 expression showed a significant increase in 
STZ group (Table II) when compared with the control 
group, specifically in the first phase (group × phase 
effect: F(1,14)=8,57, p=0.01) (Fig. 3C). 
DISCUSSION
This study showed that icv‑STZ administration in‑
creases risk related behavior and induces memory im‑
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Fig. 2. Short‑term (phase 1) and long‑term (phase 2) behavior effects evaluated by EPM. Behavior effects of icv citrate buffer (white bar) or STZ (gray bar) 
injections in the EPM test represented by mean values ± SEM of trials. Data were analyzed by repeated measures analysis of variance (ANOVA) with the 
groups (control and STZ groups) as between‑subject factor, and trials (trial 1 and 2) and phases (phases 1 and 2) as within‑subject factor. (*) Represents 
a significant difference (p<0.05). Animals from different phases showed the same behavior pattern with no significant statistical difference between them. 
The group that received the STZ showed in both an increased time percentage (A) and number of entries (B). Additionally, the STZ group showed an in‑
creased time percentage in the center square (C) in comparison to control group. Moreover, animals which received STZ exhibited a significant increase 
in the number of crosses in center square (D). The proportion of entries into closed arms was also higher in STZ group (E). P value for each parameter is 
plotted under the graphic.
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pairments as well as increases C3 gene expression in 
the hippocampus of Wistar rats. 
The EPM is usually used as a tool to evaluate anxio‑
genic or anxiolytic effects of drugs (Montgomery and 
Monkman, 1955). However, over the past years, studies 
have demonstrated other behaviors related to anxiety 
that can also be analyzed by the EPM (Carobrez and 
Bertoglio, 2005). The task has been performed to elu‑
cidate the understanding of emotional biological basis 
related to learning and memory, defensive behavior 
and anxiety disorders, such as phobia and post‑trau‑
matic stress (Lamprea et al., 2000; Carobrez et al., 2001; 
Rasmussen et al., 2001). The EPM can be also used to 
evaluate episodic memory retention when animals 
are exposed more than once to the equipment. When 
the animal is exposed to an open and elevated area 
(open arms) it is consolidated an aversive memory 
conditioned to a specific context (Sharma and Kulkar‑
ni, 1992; Tanyeri, 2014; Mutlu et al., 2015). Once the 
Fig. 3. Quantitative expression analysis of AD related genes in control (white bar) and STZ groups (gray bar). Quantification data for all genes were normal‑
ized using β‑actin as reference gene. Data are represented by mean values ± SEM and analyzes were performed by ANOVA. (*) Represents a significant 
difference (p<0.05). The relative Fold changes of mRNA expression are shown in “y axis” in relation to control phase 1 sample (defined as 1) represented by 
dashed line. Ps‑1, Apoe and Mapt gene expression did not showed significant difference between both group and phase. However, C3 showed a significant 
increased expression in STZ group, specifically in phase 1 (p=0.01).
Table II. Fold change (RQ) mean of C3 mRNA levels for each  
experimental group. 





* Represents a significant increase (p=0.01) in STZ group of Phase 1.
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animal is exposed to the maze during the first trial, 
the scores for open arms exploration usually decrease 
when the animal is re‑exposed to a second trial, sug‑
gesting an episodic memory consolidation.
Regarding the memory impairments, the data ob‑
tained in this study corroborate with findings from 
previous rodent studies that received icv‑STZ. For ex‑
ample, an increased time spent in the open arms had 
also been observed in different studies using animal 
models for Alzheimer’s disease. Jawhar et al. (2012) 
described an age‑dependent increase in the 5xFAD 
mice. Oakley et al. (2006) described a double trans‑
genic APP/PS1 mouse model that co‑expresses five 
AD mutations leading to accelerated plaque formation 
and increased Aβx‑42 production, when compared 
with wild types. Flanigan et al. (2014) reported this 
behavior in the same animal model and genotype and 
suggested that it did not reflect reduced anxiety, but 
rather abnormal avoidance of the closed arms on the 
part of transgenic and within‑session habituation to 
the closed arms on the part of wild type controls.
In the present study, rats receiving STZ also 
showed an increased time percentage in the center 
square of EPM in relation to the control group, sug‑
gesting a compromised risk assessment behavior. Rod‑
gers et al. (1997) mentioned that risk assessment is an 
important behavioral measurement, closely related to 
fear and anxiety. The biological function of acts and 
postures related to risk assessment is to advise behav‑
ioral strategies in potentially dangerous situations 
(Blanchard et al., 1991; 1993). Therefore, our results 
suggest that STZ induced impairments on risk assess‑
ment in rats when exposed to dangerous and aversive 
environmental conditions. 
Although previous studies had shown that repeat‑
ed testing did not modify the baseline measures of 
open arm exploration (Lister, 1987; File et al., 1990) 
currently, there are evidences that repeated testing 
increases the open arms avoidance during the re‑test 
(Bertoglio and Carobrez, 2000; 2002), suggesting that 
there is a learning and memory process related to the 
memory consolidation based on the previous aversive 
experience. In the current study, animals from the 
control group presented increased avoidance to the 
open arms (less open arm exploration) in the re‑test 
as described by (Bertoglio and Carobrez, 2000; 2002). 
However, STZ group showed the same exploration pat‑
tern to the open arms in the second trial when com‑
pared to the first exposure, indicating a risk related 
behavior and memory impairment, since the animals 
did not remember the aversive conditions experi‑
enced in the first trial.
Chen et al. (2012) reported that the most promi‑
nent brain abnormality in the icv‑STZ mouse, when 
compared to transgenic model (3xTg‑AD), was the 
neuroinflammation process. Current research corrob‑
orates this conclusion, since upregulation of C3 mRNA 
suggested an acute neuroinflammation in the icv STZ 
model. Chen et al. (2012) also suggest that the neuroin‑
flammation was associated to oxidative stress induced 
by STZ administration. In fact, several reports have 
showed that STZ induces oxidative stress in the brain 
and that oxidative stress is usually associated with in‑
flammation in a process known as neuroinflammation 
(Kamat et al., 2016). Indeed, Rai et al. (2014) found an 
increased level of ROS and nitrite in synaptosomal 
preparation of hippocampus and cortex, indicating 
oxidative stress in the brain areas involved with the 
regulation of memory functions. They also observed 
an increase of mRNA and protein expression in mark‑
ers of glial activation and elevated levels of pro‑in‑
flammatory cytokine (TNF‑α) in brain areas of icv STZ. 
There are different patterns of gene expression 
during AD progression since it is a multifactorial dis‑
ease (Miller et al., 2013). Changes in gene expression of 
distinct brain regions affected by the disease are com‑
mon and usually unpredictable. For this reason, ap‑
proaches that allow investigation in a molecular level 
(such as qRT‑PCR) are essential to understand molec‑
ular pathways involved in AD, which can provide new 
insights about potential therapeutic targets with mo‑
lecular characteristics (Ding et al., 2014). Therefore, 
it is important the elucidation of gene expression in 
a mRNA level, allowing to explore the dynamics be‑
tween genes and proteins. 
CONCLUSION
Therefore, the present study showed that icv STZ 
animal model presented impairments in behavioral 
functions such as anxiety, episodic memory and risk 
assessment. One month after drug administration, C3 
gene, which has an important role in inflammation, 
showed an increased expression in the STZ group, 
indicating the presence of a key inflammatory pro‑
cess related to the degenerative events on hippocam‑
pal formation. Moreover, it is important to highlight 
that plaque load may not be the best early diagnostic 
marker of AD. Therefore, other markers, such as the 
neuroinflammatories, should be explored to enable 
the track of AD progression. 
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SUPPLEMENTAL MATERIALS
Supplementary Fig. 1. (A): RNA was extracted from rat hippocampus following PureLink RNA Mini Kit® (Thermo Fisher Scientific) with trizol reagent, as 
recommended by manufacture, and its presence and integrity was evaluated by agarose gel electrophoresis 1,5%. Representative sample of each experi‑
mental group was tested: 1: Control group phase 1, 2: STZ group phase 1; 3: Control group phase 2; 4: STZ group phase 2. RNA samples presented a satis‑
factory profile, considering the presence of rRNA bands (28S and 18S). (B): Agarose gel electrophoresis 1,5% was performed in order confirm the fragment 
size generated by each primer pair. 1: 1kb DNA ladder Plus (Invitrogen); 2: PCR product amplified with β‑actin (165 bp); 3: Apoe (150 bp); 4: C3 (272 bp); 5: 
Mapt (150 bp); 6: Ps‑1 (161 bp). All samples showed an expected fragment size accordantly to each primer used.
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Supplementary Fig. 2: Melting curve of Apoe, Ps‑1, C3 and Mapt genes. The amplification specificity of each qRT‑PCR assay was confirmed by melting curve 
analysis. Each primer pair showed a single peak, indicating that the primers amplified only1 specific PCR product.
